Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Ital Biol ; 143(1): 65-79, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15844669

ABSTRACT

Sleep disturbances are found in the course of most dementing syndromes. We report a longitudinal polysomnographic and 18FDG-PET study in a 38-year-old male with FTDP17 carrying the Tau gene mutation G389R. All-night sleep EEG and wake cerebral glucose metabolism at rest (eyes/ears covered) of the preceding day were studied twice, eight months (Night 1; PET 1) and sixteen months (Night 2; PET 2) after the initial neurological evaluation. The Night 1 study showed sleep fragmentation associated to a short REM latency and a severe reduction of slow wave sleep, with relatively preserved NREM-REM sleep cycles; daytime PET 1 revealed severe cerebral glucose metabolic reductions in frontal and temporal areas, with relative preservation of remaining cortical regions and subcortical structures. On Night 2, the total sleep time was less than 5 hours, delta sleep and REM latency remained shortened and only two sleep cycles could be identified; daytime PET 2 exam revealed a greater cortical metabolic impairment and an involvement of subcortical brain regions as compared to PET 1. Post-mortem neuropathological data showed severe neuronal loss, spongiosis and gliosis that were mostly marked in cortical layers I, II, V and VI. In vivo, neurometabolic and post-mortem neuropathological data are consistent with and indicative of a severe dysfunction of intra- and trans-hemispheric regional connectivity and of cortico-thalamic circuits. These findings suggest that the decreased cortical and subcortical connectivity may have been the main pathophysiological mechanism responsible for delta sleep reduction and the cognitive decline.


Subject(s)
Brain/physiopathology , Pick Disease of the Brain/physiopathology , Sleep Wake Disorders/physiopathology , Sleep, REM/genetics , Sleep/genetics , tau Proteins/genetics , Adult , Brain/diagnostic imaging , Brain/pathology , Disease Progression , Fatal Outcome , Humans , Longitudinal Studies , Male , Nerve Degeneration/metabolism , Nerve Degeneration/pathology , Nerve Degeneration/physiopathology , Neural Pathways/metabolism , Neural Pathways/pathology , Neural Pathways/physiopathology , Pick Disease of the Brain/diagnostic imaging , Pick Disease of the Brain/genetics , Polysomnography , Positron-Emission Tomography , Sleep Wake Disorders/diagnostic imaging , Sleep Wake Disorders/genetics
2.
J Neuropathol Exp Neurol ; 63(4): 363-80, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15099026

ABSTRACT

Abnormal accumulation of ferritin was found to be associated with an autosomal dominant slowly progressing neurodegenerative disease clinically characterized by tremor, cerebellar ataxia, parkinsonism and pyramidal signs, behavioral disturbances, and cognitive decline. These symptoms may appear sequentially over a period of 4 decades. Pathologically, intranuclear and intracytoplasmic bodies were found in glia and subsets of neurons in the central nervous system as well as in extraneural tissue. Biochemical analyses of these bodies isolated from the striatum and cerebellar cortex revealed that ferritin light polypeptide (FTL) and ferritin heavy polypeptide (FTH1) were the main constituents. Molecular genetic studies revealed a 2-bp insertion mutation in exon 4 of the FTL gene. The resulting mutant polypeptide is predicted to have a carboxy terminus that is altered in amino-acid sequence and length. In tissue sections, the bodies were immunolabeled by anti-ferritin and anti-ubiquitin antibodies and were stained by Perls' method for ferric iron. Synthetic peptides homologous to the altered and wild-type carboxy termini were used to raise polyclonal antibodies. These novel antibodies as well as an antibody recognizing FTH1 immunolabeled the bodies. This study of this disorder has provided additional knowledge and insights in the growing area of ferritin-related neurodegeneration.


Subject(s)
Brain/pathology , Ferritins/genetics , Ferritins/metabolism , Neurodegenerative Diseases/genetics , Neurodegenerative Diseases/physiopathology , Adult , Amino Acid Sequence , Base Sequence , Blotting, Western , Brain/metabolism , DNA Mutational Analysis , Electrophoresis, Polyacrylamide Gel , Female , Genes, Dominant , Humans , Immunohistochemistry , Inclusion Bodies/chemistry , Inclusion Bodies/metabolism , Inclusion Bodies/ultrastructure , Magnetic Resonance Imaging , Microscopy, Electron , Molecular Sequence Data , Mutation , Neurodegenerative Diseases/metabolism , Neuroglia/metabolism , Neuroglia/pathology , Neuroglia/ultrastructure , Neurons/metabolism , Neurons/pathology , Neurons/ultrastructure , Pedigree , Protein Subunits/genetics , Protein Subunits/metabolism , Reverse Transcriptase Polymerase Chain Reaction
3.
Physiol Behav ; 63(5): 811-4, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9618003

ABSTRACT

The potential reinforcing effect of the muscarinic cholinergic agonist carbachol within the nucleus accumbens (ACB) was examined in female Wistar rats by using the technique of intracranial self-administration. Rats dose dependently self-administered solutions of 0.0-6.6 mM (in a volume of 100 nL per injection) directly into the ACB. Rats self-administered the 3.3 and 6.6 mM doses significantly more than the group given only vehicle. The caudate putamen did not support reliable self-administration of the 6.6-mM dose. Rats exhibited preference for the lever that produced infusions of 3.3 and 6.6 mM carbachol into the ACB over the lever that had no consequence. The self-infusion of the 6.6-mM dose into the ACB was inhibited by the coadministration of the muscarinic antagonist scopolamine (0.25 mM), but not by the nicotinic antagonist mecamylamine (6.6 mM). The present results suggest that direct activation of muscarinic receptors within the ACB supports self-administration and could result from reinforcement or from elicitation of a novel stimulus.


Subject(s)
Carbachol/administration & dosage , Motivation , Nucleus Accumbens/drug effects , Animals , Brain Mapping , Caudate Nucleus/drug effects , Caudate Nucleus/physiology , Dose-Response Relationship, Drug , Female , Injections , Nucleus Accumbens/physiology , Putamen/drug effects , Putamen/physiology , Rats , Rats, Wistar , Receptors, Muscarinic/drug effects , Receptors, Muscarinic/physiology , Self Administration
4.
J Neurosci ; 17(21): 8580-7, 1997 Nov 01.
Article in English | MEDLINE | ID: mdl-9334429

ABSTRACT

The objectives of this study were to examine the involvement of D1 and D2 receptors within the nucleus accumbens (ACB) in mediating reinforcement. The intracranial self-administration (ICSA) of D1 and D2 agonists was used to determine whether activating D1 and/or D2 receptors within the ACB of Wistar rats is reinforcing. At concentrations of 0.25, 0.50, and 1.0 mM (25, 50, and 100 pmol/100 nl of infusion), neither the D1 agonist R(+)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol [SKF 38393 (SKF)] hydrochloride nor the D2 agonist (-)-quinpirole (Quin) hydrochloride was self-administered into the shell region of the ACB. On the other hand, equimolar mixtures of SKF and Quin (SKF+Quin), at concentrations of 0.25, 0.50, and 1.0 mM each, were significantly self-infused into the ACB shell. The core region of the ACB did not support the ICSA of SKF+Quin at any of these concentrations. Rats increased lever pressing when the response requirement was increased from a fixed ratio 1 (FR1) to FR3, and they responded significantly more on the infusion lever than they did on the control lever. Coadministration of either 0.50 mM R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepine (SCH 23390) hydrochloride, a D1 antagonist, or 0.50 mM S(-)-sulpiride, a D2 antagonist, completely abolished the ICSA of the mixture of SKF+Quin (each at 0.50 mM) into the ACB shell. The present results suggest that concurrent activation of D1- and D2-type receptors in the shell of the ACB had a cooperative effect on DA-mediated reward processes.


Subject(s)
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology , Appetitive Behavior/drug effects , Dopamine Agonists/pharmacology , Nucleus Accumbens/physiology , Quinpirole/pharmacology , Receptors, Dopamine D1/physiology , Receptors, Dopamine D2/physiology , Reward , 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/administration & dosage , Animals , Appetitive Behavior/physiology , Benzazepines/pharmacology , Dopamine Agonists/administration & dosage , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Female , Goals , Injections , Nucleus Accumbens/cytology , Quinpirole/administration & dosage , Rats , Rats, Wistar , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D2/drug effects , Self Administration
SELECTION OF CITATIONS
SEARCH DETAIL
...